ground anaesthesia has not been fully studied, but several studies suggest that both the choice and depth of anaesthesia are important factors. For example, Savarese, Ali and Antonio (1977) observed no significant decrease in arterial pressure in 11 patients following the rapid i.v. injection of metocurine 0.2 mg kg" 1 during nitrous oxidemorphine-thiopentone anaesthesia, while Stoelting (1974) observed significant decreases in arterial pressure in four of 20 patients during nitrous oxide-halothane anaesthesia following the same dose of metocurine. Study groups for both investigations were the same except for background anaesthesia. Similarly, the magnitude of hypotension following the rapid i.v. administration of tubocurarine is affected by the depth of anaesthesia. For example, the same dose of tubocurarine (12 mg m"
2 ) produced significantly greater decreases in arterial pressure as the alveolar halothane concentration increased from 0.25 to 0.75 % (Munger, Miller and Stevens, 1974) .
The influence of background anaesthesia on the haemodynamic effects of atracurium has been studied by several investigators. Payne and Hughes (1981) studied the effects of atracurium in 62 patients, 21-78 years of age, anaesthetized with 60-66% nitrous oxide, fentanyl and thiopentone. Atracurium administered in single and divided doses at 0.05-0.6 mg kg" 1 did not produce significant changes in arterial pressure or heart rate (table  I) . However, the investigators did not clearly indicate the physical status and state of hydration of the patients nor the presence or absence of surgical stimulation. Nevertheless, the authors concluded that histamine release and related circulatory effects did not occur with atracurium, even at doses up to three times ED e5 . Rupp, Fahey and Miller (1983) also determined the haemodynamic effects of atracurium during 60% nitrous oxide, fentanyl and thiopentone anaesthesia in 30 healthy patients. During the 10 min following the rapid i.v. injection of 1 and in the presence of surgical stimulation, there were no significant changes in mean arterial pressure or heart rate. Likewise, the investigators did not detect any circulatory changes when atracurium 0.04-0.25 mg kg" 1 was rapidly injected to 25 healthy patients during 60% nitrous oxide and 0.75% end-tidal isoflurane.
Sokoll and colleagues (1983a) measured the circulatory responses following the rapid administration (less than or equal to 15 s) of atracurium 0.06-0.4 mg kg" 1 in 25 ASA class I-II patients during 60 % nitrous oxide, fentanyl and thiopentone anaesthesia. In the absence of surgical stimulation, no significant change in mean arterial pressure or heart rate occurred. In another study Sokoll and colleagues (1983b) determined the circulatory effects of the rapid i.v. administration of atracurium 0.2 or 0.4 mg kg" 1 before surgical stimulation in 16 ASA class I-II patients during 70% nitrous oxide and 0.6-0.65% end-tidal isoflurane. Following the administration of atracurium 0.2 mg kg" 1 there were no significant changes in mean arterial pressure, heart rate, cardiac and stroke index, central venous pressure, pulmonary capillary wedge pressure or systemic vascular resistance. These same variables were unchanged following atracurium 0.4 mg kg" 1 , with the exception of minimal but statistically significant {P < 0.05) reductions in heart rate and cardiac index 10 min after drug injection ( fig. 4) . No evidence for histamine release was observed in any patient. The authors concluded that the circulatory changes were clinically insignificant. Savarese and colleagues (1982) atracurium 0.4 mg kg" 1 a small but statistically significant increase in heart rate occurred (8% from control). Changes in mean arterial pressure (6% decrease) were not statistically significant. Serum histamine concentrations measured 2 min and 5 min following drug injection were unchanged from control values. The authors concluded that atracurium did not produce clinically significant haemodynamic changes at doses at least twice ED, 6 under halothane anaesthesia.
Hilgenberg, Stoelting and Harris (1983) studied the systemic vascular responses to atracurium in 15 ASA class I and II patients during 70 % nitrous oxide and 1.0-1.25 % inspired enflurane anaesthesia. During the 10 min following the rapid i.v. injection of atracurium 0.2 or 0.4 mg kg" 1 , and in the absence of surgical stimulation, there were no significant changes in heart rate, arterial pressure, cardiac output, right atrial pressure or systemic vascular resistance (tables II and III). Furthermore, no patient demonstrated a decrease in systemic mean or systolic arterial pressure greater than 6 mm Hg. Similar results were found by Hilgenberg, McCammon and Harris (1984) in a separate study of 10 ASA class III-IV patients who received atracurium 0.4 mg kg" 1 over 90 s during 70% nitrous oxide and fentanyl anaesthesia.
In contrast to the minimal to absent circulatory effects of atracurium found by most investigators, Basta, Savarese and colleagues (1982a) described dose-dependent changes in arterial pressure and heart rate following high doses (greater than twice ED 86 ) of atracurium during 65 % nitrous oxide, fentanyl and thiopentone anaesthesia. In the absence of surgical stimulation the rapid i.v. injection of atracurium 0.06-0.4 mg kg~l to ASA class I patients failed to produce any changes in mean arterial pressure or heart rate ( fig. 3) . However, atracurium 0.5 mg kg" 1 produced a 13 % decrease (not statistically significant) in mean arterial pressure and a 5.5 % increase (P < 0.05) in heart rate, while atracurium 0.6 mg kg" 1 resulted in a 20% decrease (P < 0.05) in mean arterial pressure and an 8.3 % increase (P < 0.05) in heart rate. These circulatory changes were transient, occurring 60-90 s after administration of atracurium and disappearing within 5 min. Slight facial flushing occurred, suggesting histamine release. The authors concluded that atracurium has less cardiovascular side-effects than any currently available long-acting neuromuscular blocker and that doses of one to two times ED B6 produce minimal circulatory changes.
Recently, Scott and colleagues (1984) examined several clinical strategies for preventing histamine release and the related haemodynamic responses following large doses (three times ED g6 ) of atracurium. Following induction of anaesthesia with fentanyl and thiopentone, 27 ASA class I or II patients received atracurium 0.6 mg kg" 1 by rapid bolus injection (nine patients), by slow injection over 75 s (nine patients), or by rapid bolus injection following pretreatment with histamine (H t and H,) receptor antagonists (nine patients). In the groups receiving atracurium by either slow injection or following histamine receptor antagonist drugs, no significant change in mean arterial pressure or heart rate occurred (table  IV) . Furthermore, plasma histamine concentrations were not significantly changed from control values in the treatment groups. In contrast, the mean arterial pressure decreased (18%) while the heart rate and plasma histamine increased (8% and 98%, respectively) in the control group receiving atracurium by rapid injection.
In summary, clinical doses (one to two times ED, S ) of atracurium produce little or no cardiovascular effects in ASA class I-IV patients, regardless of the inhalation anaesthetic drug. Doses greater than two times ED, 5 may produce transient but significant circulatory changes, particularly when the drug is administered by rapid injection. However, these circulatory responses may be prevented by clinical strategies designed to attenuate histamine release (slow injection or histamine receptor antagonists).
